Expert Analysis

Management of Treatment-Naive Patients

Source: CCO Independent Conference Coverage of the 2005 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Management of Treatment-Naive Patients

Program Director: John P. Phair, MD

Faculty:

Joel E. Gallant, MD, MPH
Anton L. Pozniak, MD, FRCP
Kimberly Y. Smith, MD, MPH

CME CREDIT INFORMATION

Release Date: 04/01/05

Expiration Date: 03/31/06

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss differences and similarities between firstline antiretroviral regimens in terms of efficacy and long-term patient outcome, and special considerations for developed and developing countries.
Recount data on how earlier antiretroviral treatment may affect CD4+ cell counts and subsequent treatment strategies, such as structured treatment interruption.
Describe how age, sex, adherence, host genetics and race can influence response to initial therapy.

Earn CME credit by reading the expert analysis and commentary on Management of Treatment-naive Patients. Topics covered include:

Comparison of First-Line Regimens
Effects of Age, Sex, and Adherence on Treatment Response
Mortality Risk With Specific Antiretroviral Regimens
Relationship Between Efavirenz Treatment and Race
Use of 3-Class Regimens in Treatment-Naive Patients
Use of Antiretroviral Regimens in Developing Countries
Uptake of Antiretroviral Therapy in Developed Countries
The "New York Case": Highly Resistant, Fast-Progressing HIV Infection
Antiretroviral Therapy During Acute HIV Infection
Structured Treatment Interruption

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.